Given the broad use of the SCLC-Y cell lines we now identify to be SMARCA4-UT in therapeutic studies, our findings provide new insight into potential therapeutic vulnerabilities in SMARCA4-deficient malignancies. Here, SMARCA4 is linked to small cell lung carcinoma.